Precision is participating in BTIG's Biotech Conference on Monday, August 5 at 4PM ET! Join Michael Amoroso, President & Chief Executive Officer, and Cassie Gorsuch, VP of Gene Therapy, as they explore the utilization of Precision's innovative ARCUS® platform for advancing in vivo gene editing therapies. They will discuss its capabilities in achieving sophisticated gene edits such as insertion, excision, and elimination, aimed at transforming the landscape of genetic medicine. For more information, visit https://loom.ly/aPvoj_g #GeneEditing #Biotech #DTIL
Precision BioSciences, Inc.
Biotechnology Research
Durham, North Carolina 20,033 followers
Dedicated to Improving Life.
About us
Precision BioSciences, Inc. (Nasdaq: DTIL) is a pre-clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com.
- Website
-
http://www.precisionbiosciences.com
External link for Precision BioSciences, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Durham, North Carolina
- Type
- Public Company
- Founded
- 2006
- Specialties
- Gene Editing and Gene Therapy
Locations
-
Primary
302 East Pettigrew Street
Durham, North Carolina 27701, US
Employees at Precision BioSciences, Inc.
Updates
-
July 28th marked #WorldHepatitisDay! Precision's Scientific Advisory Board member, Jordan Feld, M.D., MPH, FAASLD, honors the occasion by highlighting the burdens and the stigmas that people living with hepatitis B face and speaking about Precision's innovative approach to potentially combat hepatitis B infection around the world. Preclinical safety data supports advancement of Precision's PBGENE-HBV program to clinical trials as a potentially curative, finite treatment for chronic hepatitis B with IND and/or CTA on-track for submission in 2024. To learn more, visit https://loom.ly/JGM0mXw. #HepatitisBTreatment #GeneEditing #Biotech #DTIL
-
Approximately 300 million people globally and more than 1 million people in the US are estimated to have chronic hepatitis B infection. An estimated 15% to 40% of patients with HBV infections may develop complications, such as cirrhosis, liver failure, or liver cancer, which account for the majority of HBV-related deaths. Since the mid-1990s, there has been minimal innovation in addressing this issue. At Precision Biosciences, we are committed to addressing this challenge by pioneering bold initiatives for the infected patient populations through revolutionary genome editing treatments. #WorldHepatitisDay #HepatitisBTreatment #GeneEditing #Biotech #DTIL
-
Precision BioSciences, Inc. reposted this
Have you heard? Precision BioSciences has been added to the Russell Microcap Index! The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Learn more: https://loom.ly/25F3f18 #GeneEditing #Biotech #DTIL
-
-
Have you heard? Precision BioSciences has been added to the Russell Microcap Index! The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Learn more: https://loom.ly/25F3f18 #GeneEditing #Biotech #DTIL
-
-
Are you free on July 15 at 12:30 pm ET (9:30 am PT)? Join Precision BioSciences for its presentation at the JonesTrading Healthcare Seaside Summit! Discover how we have distinguished ourselves as a cutting-edge gene editing company, leveraging our innovative proprietary ARCUS® platform to advance in vivo gene editing therapies. Register today! https://loom.ly/UwrhRSU *A live webcast of the presentation will also be accessible on Precision’s website in the Investors section under Events & Presentations at https://lnkd.in/epAiWMAa #GeneEditing #Biotech #DTIL
-
-
We're honored to have Wendy Shoop, PhD, represent the Precision team at the United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine 2024 Conference! Wendy shared details from our lead PBGENE-PMM program targeting m.3243 mitochondrial disease and showcased the broader applicability of ARCUS to target other mitochondrial mutations. Given ARCUS’ ability to target the root cause of disease, we are excited by our data generated to date and are working diligently to advance PBGENE-PMM towards an Investigational New Drug and/or Clinical Trial Application in 2025. Learn more, https://loom.ly/f8wGqgY #GeneEditing #MitoMed24 #DTIL
-
-
World-class clinical investigators added to Precision’s Scientific Advisory Board as PBGENE-HBV Program Nears Clinical Readiness! As crucial milestones approach, Dr. Mark Sulkowski and Dr. Jordan Feld have joined Precision's Scientific Advisory Board alongside Dr. Raymond Schinazi, an esteemed trailblazer in hepatitis treatments. Together, their significant contributions to the field of hepatitis B solidify their positions as thought-leaders, and we are pleased to welcome advisors of such high caliber to our team. Meet our SAB Board 👉 https://loom.ly/SCKqqLs Read Precision's latest PR 👉 https://loom.ly/JGM0mXw #GeneEditing #Biotech #DTIL
-
Precision's Michael Amoroso, CEO; Jeff Smith, Co-Founder & CRO; and Alex Kelly, CFO, will attend and present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wed, Jun 12th at 10 a.m. ET. Sign up today to join the webcast: tinyurl.com/4u8nt7nt #GeneEditing #Biotech #DTIL
-
-
Here's what the Precision team has been up to this week! ✅ Precision presented late-breaking data at the European Association for the Study of the Liver (EASL) in Milan. ✅ Precision released preclinical data highlighting PBGENE-HBV's ability to specifically cut HBV DNA leading to elimination of cccDNA and inactivation of integrated HBV DNA without impacting any sites in the human genome, including no editing-associated translocations in HBV infected primary human hepatocytes; PBGENE-HBV was well tolerated across multiple administrations with no off-target editing observed; preclinical safety data supports advancement of PBGENE-HBV to clinical trials as a potentially curative, finite treatment for chronic hepatitis B with IND and/or CTA on-track for submission in 2024. ✅ Precision's Emily Harrison, PhD, Senior Scientist - Hepatitis Research Leader, and Cassie Gorsuch, PhD, VP Gene Therapy, spoke at The HBV Forum in Milan about the Company's PBGENE-HBV program. The Company's work to date continues to highlight the potential of PBGENE-HBV as a curative treatment for chronic hepatitis B and further validates our ARCUS® platform to potentially deliver safe and efficacious in vivo gene editing therapies. Read our latest press release: https://loom.ly/ZFKBnGo #GeneEditing #Biotech #DTIL
-